Evidence map›Paper›PMID 30566493›Full record

ArticlePloS one2018

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Carolina Beltran-Pavez, Carolina B Ferreira, Alberto Merino-Mansilla, Amanda Fabra-Garcia, Maria Casadella, Marc Noguera-Julian, Roger Paredes, Alex Olvera, Isabel Haro, Christian Brander and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. A review of vaccine effects on women in light of the COVID-19 pandemic.Taiwanese journal of obstetrics & gynecology · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Carolina Beltran-PavezAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
Carolina B FerreiraAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
Alberto Merino-MansillaAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
Amanda Fabra-GarciaAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0001-6663-213X
Maria CasadellaHIVACAT, Barcelona, Spain.
Marc Noguera-JulianHIVACAT, Barcelona, Spain.
Roger ParedesHIVACAT, Barcelona, Spain.
Alex OlveraHIVACAT, Barcelona, Spain.ORCID 0000-0002-9934-5759
Isabel HaroUnit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain.ORCID 0000-0001-8677-2340
Christian BranderHIVACAT, Barcelona, Spain.
Felipe GarciaAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
Jose M GatellAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
Eloisa YusteAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
Victor Sanchez-MerinoAIDS Research Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0001-9400-427X
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat de Vic - Universitat Central de Catalunya · ESHospital Clínic de Barcelona · ESIrsiCaixa · ESInstitute of Advanced Chemistry of Catalonia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that the ability of an epitope to elicit effective humoral immunity depends on its exposure on the virion, we have used a reverse genetics approach to select variants from an HIV-1 AC10_29 randomly mutated envelope library that showed increased affinity for a selected bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were analyzed by deep-sequencing showing a small number of dominant changes, including the loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accordingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs 4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the amino acids specific for the selected variant are associated with an increased sensitivity for 4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29 env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detectable neutralizing activity in immunized rabbits, one animal showed antibody response to the 4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV envelope immunogen sequences that direct antibody responses to specific envelope regions.

Indexed as

AnimalsAntibodies, NeutralizingAntibody FormationBlotting, WesternCryoelectron MicroscopyEnzyme-Linked Immunosorbent AssayFemaleHEK293 CellsHIV-1HIV AntibodiesHumansImmunity, HumoralImmunizationMiceMice, Inbred BALB CNeutralization TestsAntibodies, NeutralizingHIV AntibodiesVaccines, Virus-Like Particle

Identifiers

PMID30566493
PMCPMC6300218
OpenAlexW2905358223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.